ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis

Chen, Tingting; Shan, Lizhu

doi:10.1080/13880209.2019.1660383

Cited by 17 publications

(17 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The purpose of this study was to demonstrate whether SQFZ improved chemotherapeutic resistance induced by cisplatin through the PI3K signalling pathway in drug-resistant breast cancer. SQFZ improves clinical efficacy, inhibits immunosuppression, and reduces toxicity in combination with chemotherapy drugs for breast cancer [ 26 , 27 ]. In the present study, we investigated the anticancer mechanisms of SQFZ action, particularly the signalling pathways involved in the reversal of drug resistance.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer

Yan

Shi

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Shenqi Fuzheng injection (SQFZ) combined with chemotherapy can sensitize tumour cells. However, the mechanisms underlying SQFZ’s effects remain unknown. In human breast cancer cell lines and M2 macrophages, we showed that SQFZ was a significantly potent agent of sensitization. Methods The human breast cancer cell line, MDA-MB-231/DDP, and the human acute leukaemia mononuclear cell line, THP-1, were used. MDA-MB-231/DDP breast cancer xenografts were established to monitor tumour growth. Resistance-associated proteins were examined by western blotting. Levels of cytokines and chemokines were detected by ELISA. Cell viability was measured using the MTT assay. Apoptosis was detected by flow cytometric analysis. Results SQFZ significantly enhanced the capability of cisplatin to reduce tumour mass. SQFZ and cisplatin decreased the expression of CD206 by 1.89-fold and increased that of CD86 by 1.76-fold as compared to cisplatin alone. The levels of PGE2, IL-6, and CCL1 decreased significantly, and the activation of p-PI3K and the expressions of P-gp and ABCG2 were also inhibited by SQFZ in combination with cisplatin treatment in vivo. The survival following cisplatin administration of 60 μM and 120 μM reduced significantly in the presence of SQFZ in MDA-MB-231/DDP and M2 co-cultured cells. IGF-1, a PI3K activator, combined with SQFZ weakened the effects of SQFZ-induced apoptosis from 28.7% to 10.5%. The effects of IGF-1 on increasing the expressions of P-gp, ABCG2, and Bcl-2, and decreasing that of Bax were reversed by SQFZ. Conclusion Our findings provide evidence that SQFZ is a potential therapeutic drug for cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Clinical trials have demonstrated the efficacy of SQFZ combined with chemotherapy in sensitizing tumour cells and lowering toxicity [ 24 ]. SQFZ can also reduce the side effects of chemotherapy and improve the quality of life of patients with cancer [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer

Yan

Shi

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…SQFZ is concocted from Radix Astragali (Chinese name: Huangqi) and Radix Codonopsis (Chinese name: Dangshen), and is clinically suggested as a complementary treatment of chemotherapy, and clinical practices suggest that SQFZ has therapeutic effects on cardiovascular diseases ( 75 , 76 ). Intensive researches reported that SQFZ exerts protective through improving myocardial energy metabolism, inhibiting cell adhesion and inflammatory reaction, and reducing myocardial apoptosis and avoiding ventricular remodel ( 77 ).…”

Section: Discussionmentioning

confidence: 99%

“…SM, a commonly used CPMs for treating cardiovascular diseases in the clinic, consists of extractions from Red Ginseng (Chinese name: Hongshen) and Radix Ophiopogonis (Chinese name: Maidong) (58,59). It was widely used in cardiovascular diseases and has a certain synergistic effect when combined with (75,76). Intensive researches reported that SQFZ exerts protective through improving myocardial energy metabolism, inhibiting cell adhesion and inflammatory reaction, and reducing myocardial apoptosis and avoiding ventricular remodel (77).…”

Section: The Network Pharmacology Analysis Of Cpms Against Aicmentioning

confidence: 99%

Comparative efficacy and pharmacological mechanism of Chinese patent medicines against anthracycline-induced cardiotoxicity: An integrated study of network meta-analysis and network pharmacology approach

Rao

Wang

Lin

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundThis study aimed to evaluate the efficacy of Chinese patent medicines (CPMs) combined with dexrazoxane (DEX) against anthracycline-induced cardiotoxicity (AIC) and further explore their pharmacological mechanism by integrating the network meta-analysis (NMA) and network pharmacology approach.MethodsWe searched for clinical trials on the efficacy of DEX + CPMs for AIC until March 10, 2023 (Database: PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure, China Science and Technology Journal and China Online Journals). The evaluating outcomes were cardiac troponin I (cTnI) level, creatine kinase MB (CK-MB) level, left ventricular ejection fraction (LVEF) value, and electrocardiogram (ECG) abnormal rate. Subsequently, the results of NMA were further analyzed in combination with network pharmacology.ResultsWe included 14 randomized controlled trials (RCTs) and 1 retrospective cohort study (n = 1,214), containing six CPMs: Wenxinkeli (WXKL), Cinobufotalin injection (CI), Shenqifuzheng injection (SQFZ), Shenmai injection (SM), Astragalus injection (AI) and AI + CI. The NMA was implemented in Stata (16.0) using the mvmeta package. Compared with using DEX only, DEX + SM displayed the best effective for lowering cTnI level (MD = −0.44, 95%CI [−0.56, −0.33], SUCRA 93.4%) and improving LVEF value (MD = 14.64, 95%CI [9.36, 19.91], SUCRA 98.4%). DEX + SQFZ showed the most effectiveness for lowering CK-MB level (MD = −11.57, 95%CI [−15.79, −7.35], SUCRA 97.3%). And DEX + AI + CI has the highest effectiveness for alleviating ECG abnormalities (MD = −2.51, 95%CI [−4.06, −0.96], SUCRA 96.8%). So that we recommended SM + DEX, SQFZ + DEX, and DEX + AI + CI as the top three effective interventions against AIC. Then, we explored their pharmacological mechanism respectively. The CPMs' active components and AIC-related targets were screened to construct the component-target network. The potential pathways related to CPMs against AIC were determined by KEGG. For SM, we identified 118 co-targeted genes of active components and AIC, which were significantly enriched in pathways of cancer pathways, EGFR tyrosine kinase inhibitor resistance and AGE-RAGE signaling pathway in diabetic complications. For SQFZ, 41 co-targeted genes involving pathways of microRNAs in cancer, Rap1 signaling pathway, MAPK signaling pathway, and lipid and atherosclerosis. As for AI + CI, 224 co-targeted genes were obtained, and KEGG analysis showed that the calcium signaling pathway plays an important role except for the consistent pathways of SM and SQFZ in anti-AIC.ConclusionsDEX + CPMs might be positive efficacious interventions from which patients with AIC will derive benefits. DEX + SM, DEX + SQFZ, and DEX + AI + CI might be the preferred intervention for improving LVEF value, CK-MB level, and ECG abnormalities, respectively. And these CPMs play different advantages in alleviating AIC by targeting multiple biological processes.

show abstract

“…At present, traditional Chinese medicine (TCM) has become a common method for clinical treatment of NSCLC [5] . Some studies have confirmed that the combination of Chinese medicine and chemotherapy can improve the clinical treatment effect, achieve the effect of increasing efficiency and reducing toxicity, significantly reduce the adverse reactions caused by chemotherapy, improve the tolerance of chemotherapy, and improve the quality of life of patients [6–8] …”

Section: Introductionmentioning

confidence: 99%

Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer

et al. 2021

View full text Add to dashboard Cite

Background: Lung cancer is the leading cause of death among cancer patients worldwide. Close to 85% of lung cancer pathology types are nonsmall cell lung cancer (NSCLC). With advances in medicine, the survival rate of early-stage NSCLC has improved. Nevertheless, about 70% of patients are diagnosed at an advanced stage, and chemotherapy is the primary treatment option. Chemotherapy causes toxic side effects such as bone marrow suppression, gastrointestinal reactions, and damage to vital organs, which are difficult for patients to tolerate. Many published literatures have reported that Shenmai injection (SMI) combined with platinum-containing first-line chemotherapy regimen for NSCLC can improve the recent efficacy, reduce toxic side effects and improve the quality of life. However, most of the studies were small samples and lacked persuasive power, while controversies existed among individual studies. Therefore, this study used meta-analysis to further evaluate the effects of SMI combined with platinum-containing first-line chemotherapy on the quality of life, immune function and prognosis of patients with NSCLC.Methods: Wanfang, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database, PubMed, Embase, and Web of Science databases were searched. The search was scheduled from the establishment of the database to September 2021. All randomized controlled trials comparing SMI in combination with platinum-containing first-line chemotherapy to platinum-containing first-line chemotherapy alone for the treatment of NSCLC were searched and evaluated for inclusion. Two investigators independently performed study selection, data extraction and synthesis. The Cochrane Risk of Bias tool was used to assess the risk of bias in the randomized controlled trials. Stata 16.0 software was used for meta-analysis.Results: The results of this meta-analysis will be submitted to a peer-reviewed journal for publication. Conclusion:This study comprehensively evaluated the effects of SMI combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis in patients with NSCLC to provide an evidence-based basis for clinical practice.Ethics and dissemination: The private information from individuals will not be published. This systematic review should also not damage participants' rights. Ethical approval was not available. The results may be published in a peer-reviewed journal or disseminated in relevant conferences.

show abstract

ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis

Cited by 17 publications

References 34 publications

Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer

Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer

Comparative efficacy and pharmacological mechanism of Chinese patent medicines against anthracycline-induced cardiotoxicity: An integrated study of network meta-analysis and network pharmacology approach

Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer

Contact Info

Product

Resources

About